X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PFIZER - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PFIZER DR. REDDYS LAB/
PFIZER
 
P/E (TTM) x 26.8 24.0 111.7% View Chart
P/BV x 2.8 3.8 72.4% View Chart
Dividend Yield % 1.0 0.9 120.8%  

Financials

 DR. REDDYS LAB   PFIZER
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
PFIZER
Mar-16
DR. REDDYS LAB/
PFIZER
5-Yr Chart
Click to enlarge
High Rs4,3832,724 160.9%   
Low Rs2,7501,611 170.7%   
Sales per share (Unadj.) Rs920.1440.9 208.7%  
Earnings per share (Unadj.) Rs126.148.7 259.0%  
Cash flow per share (Unadj.) Rs183.075.8 241.5%  
Dividends per share (Unadj.) Rs20.0015.00 133.3%  
Dividend yield (eoy) %0.60.7 81.0%  
Book value per share (Unadj.) Rs685.8462.9 148.1%  
Shares outstanding (eoy) m170.6145.75 372.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.94.9 78.8%   
Avg P/E ratio x28.344.5 63.5%  
P/CF ratio (eoy) x19.528.6 68.1%  
Price / Book Value ratio x5.24.7 111.1%  
Dividend payout %15.930.8 51.5%   
Avg Mkt Cap Rs m608,48199,163 613.6%   
No. of employees `00021.72.9 750.1%   
Total wages/salary Rs m31,8742,758 1,155.9%   
Avg. sales/employee Rs Th7,244.46,981.7 103.8%   
Avg. wages/employee Rs Th1,470.9954.5 154.1%   
Avg. net profit/employee Rs Th992.8771.1 128.8%   
INCOME DATA
Net Sales Rs m156,97820,170 778.3%  
Other income Rs m2,693857 314.1%   
Total revenues Rs m159,67121,028 759.3%   
Gross profit Rs m34,5874,310 802.5%  
Depreciation Rs m9,7051,239 783.5%   
Interest Rs m8245 15,846.2%   
Profit before tax Rs m26,7513,923 681.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m5,2371,794 291.9%   
Profit after tax Rs m21,5142,228 965.7%  
Gross profit margin %22.021.4 103.1%  
Effective tax rate %19.645.7 42.8%   
Net profit margin %13.711.0 124.1%  
BALANCE SHEET DATA
Current assets Rs m118,20116,299 725.2%   
Current liabilities Rs m68,3687,594 900.3%   
Net working cap to sales %31.743.2 73.6%  
Current ratio x1.72.1 80.6%  
Inventory Days Days6065 91.9%  
Debtors Days Days9726 376.2%  
Net fixed assets Rs m72,2658,622 838.2%   
Share capital Rs m853458 186.4%   
"Free" reserves Rs m111,54820,722 538.3%   
Net worth Rs m117,00921,180 552.5%   
Long term debt Rs m10,69025 42,760.0%   
Total assets Rs m200,10429,137 686.8%  
Interest coverage x33.5755.5 4.4%   
Debt to equity ratio x0.10 7,740.0%  
Sales to assets ratio x0.80.7 113.3%   
Return on assets %11.27.7 145.7%  
Return on equity %18.410.5 174.8%  
Return on capital %21.619.0 113.7%  
Exports to sales %46.30.1 77,756.0%   
Imports to sales %9.017.5 51.2%   
Exports (fob) Rs m72,61812 605,150.0%   
Imports (cif) Rs m14,0503,526 398.5%   
Fx inflow Rs m75,40552 145,992.3%   
Fx outflow Rs m27,115140 19,370.6%   
Net fx Rs m48,290-88 -54,670.0%   
CASH FLOW
From Operations Rs m40,4763,436 1,177.9%  
From Investments Rs m-19,421-6,991 277.8%  
From Financial Activity Rs m-17,009-619 2,748.7%  
Net Cashflow Rs m4,046-4,174 -96.9%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.4 7.5 72.0%  
FIIs % 35.3 4.9 720.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.7 64.6%  
Shareholders   75,885 85,207 89.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 22, 2017 09:19 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS